The B7-H3–Targeting Antibody–Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models

Kendsersky, Nathan M., Lindsay, Jarrett, Kolb, E. Anders, Smith, Malcolm A., Teicher, Beverly A., Erickson, Stephen W., Earley, Eric J., Mosse, Yael P. +15 more·2021·Clinical Cancer Research
DOI 10.1158/1078-0432.ccr-20-4221

Cited by (120)

Items 101–120 of 120

  1. Tumor–Immune Interactions in Pediatric Oral Rhabdomyosarcoma: A Narrative Review on Immuno-Oncology and Emerging Therapies
    Omar El Meligy, Noha Mousaad Elemam, Wael Abdo Hassan, Iman Mamdouh Talaat · 2025 · Children
  2. Tumor Microenvironment and Immune Response Against Wilms Tumor: Evasion Mechanisms and Implications for Immunotherapeutic Approaches
    Claudia Cantoni, Valerio Gaetano Vellone, Barbara Cafferata, Gabriele Gaggero, Martina Serra, Filippo Spreafico, Cristina Bottino, Grazia Maria Spaggiari · 2026 · Cancers
  3. Enhancing the efficacy of B7-H3-targeting antibody-drug conjugate DS-7300a in TP53-deficient tumors by inducing ferroptosis
    Javier Leo, Feiyu Chen, Shi Wei, X Liang, Chenling Meng, Qianlin Gu, Yaman Albittar, Zhen Fan, Jie Zhang, Boyi Gan et al. · 2026 · Oncogene
  4. Targeted Fluorogenic Cyanine Carbamates Enable In Vivo Analysis of Antibody-Drug Conjugate Linker Chemistry
    Syed Muhammad Usama, Sierra C. Marker, Donald R. Caldwell, Nimit L. Patel, Yang Feng, Joseph D. Kalen, Brad St. Croix, Martin J. Schnermann · 2021
  5. Targeted Fluorogenic Cyanine Carbamates Enable In Vivo Analysis of Antibody-Drug Conjugate Linker Chemistry
    Syed Muhammad Usama, Sierra C. Marker, Donald Caldwell, Nimit L. Patel, Yan Feng, Joseph D. Kalen, Martin J. Schnermann, Brad St. Croix · 2021
  6. Precision cancer therapy by molecular profiling – A Theoretical Study
    V. Sah · 2021
  7. Retinoblastoma genetics: A Survey
    V. Sah · 2021
  8. Advances and Problems in Preclinical Models for Childhood Cancer
    Vijayalaxmi Sah · 2021
  9. Data from Evaluation of the DLL3-targeting Antibody–Drug Conjugate Rovalpituzumab Tesirine in Preclinical Models of Neuroblastoma
    Kateryna Krytska, Colleen E. Casey, Jennifer E. Pogoriler, Daniel Martı́nez, Komal S. Rathi, Alvin Farrel, Esther R. Berko, Matthew Tsang, Renata R. Sano, Nathan M. Kendsersky et al. · 2023
  10. Data from Evaluation of the DLL3-targeting Antibody–Drug Conjugate Rovalpituzumab Tesirine in Preclinical Models of Neuroblastoma
    Kateryna Krytska, Colleen E. Casey, Jennifer E. Pogoriler, Daniel Martı́nez, Komal S. Rathi, Alvin Farrel, Esther R. Berko, Matthew Tsang, Renata R. Sano, Nathan M. Kendsersky et al. · 2023
  11. WITHDRAWN: Next generation immune checkpoints
    Natalia Muñoz Perez, Kirsten Moziak, Allison M. Martin · 2024 · Elsevier eBooks
  12. Immunomodulatory Mechanisms Impacting the Activity and Fate of Natural Killer Cells in Cancer
    Cristina Bottino, Alessandra Dondero, Chiara Vitale, Roberta Castriconi · 2025 · Springer eBooks
  13. Therapeutic Targeting of Osteosarcoma and Lung Metastases in Preclinical Models Using a CD24 Antibody‐Drug Conjugate
    Peng Guo, Yuxuan Li, Jing Huang, Liming Jin, Xing Liu, Dawei He, Marsha A. Moses · 2025 · Advanced Therapeutics
  14. Fc-Engineered B7-H3 Antibody with Prolonged Serum Half-Life for Enhanced Cancer Therapy
    Huiting Wu, Mengjia Zhang, Tingting Wang, Jinping Zhao, Gao Cheng, Zhihao Wang, Kaixuan Zhu, Chang Liu, Yongwei Ding, Xuhua Zhang et al. · 2025 · Molecular Pharmaceutics
  15. Improve the Efficacy of B7-H3-Targeting Antibody-Drug Conjugate DS-7300a in TP53-deficient Tumors by Inducing Ferroptosis
    Javier Leo, Feiyu Chen, Wei Shi, Xin Liang, Chenling Meng, Qianlin Gu, Yaman Albittar, Zhen Fan, Jie Zhang, Boyi Gan et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  16. Dual metabolic intervention nanoplatform co-delivering BAY-876 and L-cystine for Wilms tumor therapy via disulfidptosis-associated cytoskeletal collapse
    Junyi Luo, Tao Mi, Jinkui Wang, Liming Jin, YongLin Mou, Xiaohai Hu, LI Lei, Jiaxin Rao, Peng Guo, Dawei He · 2026 · Journal of Nanobiotechnology
  17. Genomic landscape and tumor immune microenvironment of osteosarcoma: Bridging mechanistic insights to precision therapeutics
    Chenchen Yang, Yiyang Yu, Yaqi Wang, Zhenyu Cai, Yuwei Zhao, Hengyue Ma, Jie Xu, Huaiqiu Zhu, Tingting Ren, Xiaodong Tang et al. · 2026 · Bone Reports
  18. Paediatric Therapeutic Development Workshop on rhabdomyosarcoma
    Joseph S. Baxter, Claudia Montiel-Equihua, Jan J. Molenaar, Jamie M. Aye, Gianni Bisogno, Patricia Blanc, Willemijn B. Breunis, Julia Chisholm, Jacquelyn N. Crane, Sam Daems et al. · 2026 · British Journal of Cancer
  19. Clinical and therapeutic relevance of B7-H3 in sarcomas: molecular insights from a systematic review
    Nouran Alwisi, Mohammad Abdel Hamid, Dahab Ghith, Salam Alshare, Lujain Adham, Samiha Sami, Giridhara Rathnaiah Babu, Semir Vranić · 2026 · Journal of drug targeting
  20. The Osteosarcoma Tumor Microenvironment: Supportive of Tumor Progression, Hostile to Immunity, but Therapeutically Targetable
    Lidia Tarone, Irene Fiore Merighi, Elisa Tirtei, Davide Giacobino, Emanuela Maria Morello, Federica Cavallo, Federica Riccardo · 2026 · Cancers